Cerebrospinal Fluid 7-Ketocholesterol Level is Associated with Amyloid-β42 and White Matter Microstructure in Cognitively Healthy Adults.


Journal

Journal of Alzheimer's disease : JAD
ISSN: 1875-8908
Titre abrégé: J Alzheimers Dis
Pays: Netherlands
ID NLM: 9814863

Informations de publication

Date de publication:
2020
Historique:
pubmed: 17 6 2020
medline: 8 5 2021
entrez: 16 6 2020
Statut: ppublish

Résumé

Abnormal cholesterol metabolism changes the neuronal membrane and may promote amyloidogenesis. Oxysterols in cerebrospinal fluid (CSF) are related to Alzheimer's disease (AD) biomarkers in mild cognitive impairment and dementia. Cholesterol turnover is important for axonal and white matter (WM) microstructure maintenance. We aim to demonstrate that the association of oxysterols, AD biomarkers, and WM microstructure occurs early in asymptomatic individuals. We studied the association of inter-individual variability of CSF 24-hydroxycholesterol (24-OHC), 27-hydroxycholesterol (27-OHC), 7-ketocholesterol (7-KC), 7β-hydroxycholesterol (7β-OHC), amyloid-β42 (Aβ42), total-tau (t-tau), phosphorylated-tau (p-tau), neurofilament (NfL), and WM microstructure using diffusion tensor imaging, generalized linear models and moderation/mediation analyses in 153 healthy adults. Higher 7-KC levels were related to lower Aβ42, indicative of greater AD pathology (p = 0.041) .  Higher 7-KC levels were related to lower fractional anisotropy (FA) and higher mean (MD), axial (AxD), and radial (RD) diffusivity. 7-KC modulated the association between AxD and NfL in the corpus callosum splenium (B = 39.39, p = 0.017), genu (B = 68.64, p = 0.000), and fornix (B = 10.97, p = 0.000). Lower Aβ42 levels were associated to lower FA and higher MD, AxD, and RD in the fornix, corpus callosum, inferior longitudinal fasciculus, and hippocampus. The association between AxD and Aβ42 was moderated by 7K-C (p = 0.048). This study adds clinical evidence to support the role of 7K-C on axonal integrity and the involvement of cholesterol metabolism in the Aβ42 generation process.

Sections du résumé

BACKGROUND
Abnormal cholesterol metabolism changes the neuronal membrane and may promote amyloidogenesis. Oxysterols in cerebrospinal fluid (CSF) are related to Alzheimer's disease (AD) biomarkers in mild cognitive impairment and dementia. Cholesterol turnover is important for axonal and white matter (WM) microstructure maintenance.
OBJECTIVE
We aim to demonstrate that the association of oxysterols, AD biomarkers, and WM microstructure occurs early in asymptomatic individuals.
METHODS
We studied the association of inter-individual variability of CSF 24-hydroxycholesterol (24-OHC), 27-hydroxycholesterol (27-OHC), 7-ketocholesterol (7-KC), 7β-hydroxycholesterol (7β-OHC), amyloid-β42 (Aβ42), total-tau (t-tau), phosphorylated-tau (p-tau), neurofilament (NfL), and WM microstructure using diffusion tensor imaging, generalized linear models and moderation/mediation analyses in 153 healthy adults.
RESULTS
Higher 7-KC levels were related to lower Aβ42, indicative of greater AD pathology (p = 0.041) .  Higher 7-KC levels were related to lower fractional anisotropy (FA) and higher mean (MD), axial (AxD), and radial (RD) diffusivity. 7-KC modulated the association between AxD and NfL in the corpus callosum splenium (B = 39.39, p = 0.017), genu (B = 68.64, p = 0.000), and fornix (B = 10.97, p = 0.000). Lower Aβ42 levels were associated to lower FA and higher MD, AxD, and RD in the fornix, corpus callosum, inferior longitudinal fasciculus, and hippocampus. The association between AxD and Aβ42 was moderated by 7K-C (p = 0.048).
CONCLUSION
This study adds clinical evidence to support the role of 7K-C on axonal integrity and the involvement of cholesterol metabolism in the Aβ42 generation process.

Identifiants

pubmed: 32538843
pii: JAD200105
doi: 10.3233/JAD-200105
doi:

Substances chimiques

Amyloid beta-Peptides 0
Biomarkers 0
Ketocholesterols 0
Peptide Fragments 0
amyloid beta-protein (1-42) 0
7-ketocholesterol O7676FE78M

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

643-656

Auteurs

Ane Iriondo (A)

Center for Research and Advanced Therapies, CITA-Alzheimer Foundation, Donostia-San Sebastian, Gipuzkoa, Spain.

Maite García-Sebastian (M)

Center for Research and Advanced Therapies, CITA-Alzheimer Foundation, Donostia-San Sebastian, Gipuzkoa, Spain.

Arantzazu Arrospide (A)

Gipuzkoa Primary Care - Integrated Health Care Organizations Research Unit, Alto Deba Integrated Health Care Organisation, Nafarroa Hiribidea, Arrasate, Gipuzkoa, Spain.
Biodonostia Health Research Institute, Paseo Doctor Begiristain, Donostia, San Sebastian, Spain.

Maria Arriba (M)

Center for Research and Advanced Therapies, CITA-Alzheimer Foundation, Donostia-San Sebastian, Gipuzkoa, Spain.

Sara Aurtenetxe (S)

Center for Research and Advanced Therapies, CITA-Alzheimer Foundation, Donostia-San Sebastian, Gipuzkoa, Spain.

Myriam Barandiaran (M)

Center for Research and Advanced Therapies, CITA-Alzheimer Foundation, Donostia-San Sebastian, Gipuzkoa, Spain.

Montserrat Clerigue (M)

Center for Research and Advanced Therapies, CITA-Alzheimer Foundation, Donostia-San Sebastian, Gipuzkoa, Spain.

Mirian Ecay-Torres (M)

Center for Research and Advanced Therapies, CITA-Alzheimer Foundation, Donostia-San Sebastian, Gipuzkoa, Spain.

Ainara Estanga (A)

Center for Research and Advanced Therapies, CITA-Alzheimer Foundation, Donostia-San Sebastian, Gipuzkoa, Spain.

Alazne Gabilondo (A)

Center for Research and Advanced Therapies, CITA-Alzheimer Foundation, Donostia-San Sebastian, Gipuzkoa, Spain.

Andrea Izagirre (A)

Center for Research and Advanced Therapies, CITA-Alzheimer Foundation, Donostia-San Sebastian, Gipuzkoa, Spain.
Department of Nursing II, Faculty of Medicine and Nursing, University of the Basque Country (UPV/EHU), Spain.

Jon Saldias (J)

Center for Research and Advanced Therapies, CITA-Alzheimer Foundation, Donostia-San Sebastian, Gipuzkoa, Spain.

Mikel Tainta (M)

Center for Research and Advanced Therapies, CITA-Alzheimer Foundation, Donostia-San Sebastian, Gipuzkoa, Spain.

Jorge Villanua (J)

Center for Research and Advanced Therapies, CITA-Alzheimer Foundation, Donostia-San Sebastian, Gipuzkoa, Spain.

Kaj Blennow (K)

Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at University of Gothenburg, Mölndal, Sweden.
Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.

Henrik Zetterberg (H)

Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at University of Gothenburg, Mölndal, Sweden.
Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.
Department of Neurodegenerative Disease, UCL Institute of Neurology, London, United Kingdom.
UK Dementia Research Institute at UCL, London, United Kingdom.

Javier Mar (J)

Gipuzkoa Primary Care - Integrated Health Care Organizations Research Unit, Alto Deba Integrated Health Care Organisation, Nafarroa Hiribidea, Arrasate, Gipuzkoa, Spain.
Biodonostia Health Research Institute, Paseo Doctor Begiristain, Donostia, San Sebastian, Spain.

Beatriz Abad-García (B)

Central Analysis Service, Faculty of Science and Technology, University of the Basque Country (UPV/EHU), Leioa, Bizkaia, Spain.

Irundika H K Dias (IHK)

Aston Medical Research Institute, Aston Medical School, Aston University, Birmingham, UK.

Felix M Goñi (FM)

Departamento de Bioquímica, University of the Basque Country (UPV/EHU) and Instituto Biofisika (CSIC, UPV/EHU), Leioa, Bizkaia, Spain.

Pablo Martínez-Lage (P)

Center for Research and Advanced Therapies, CITA-Alzheimer Foundation, Donostia-San Sebastian, Gipuzkoa, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH